Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice

Satoshi Tanaka, Hayato Hikita, Tomohide Tatsumi, Ryotaro Sakamori, Yasutoshi Nozaki, Sadatsugu Sakane, Yuto Shiode, Tasuku Nakabori, Yoshinobu Saito, Naoki Hiramatsu, Keisuke Tabata, Tsuyoshi Kawabata, Maho Hamasaki, Hidetoshi Eguchi, Hiroaki Nagano, Tamotsu Yoshimori, Tetsuo Takehara

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide. It encompasses a spectrum ranging from simple steatosis to fatty liver with hepatocellular injury, termed nonalcoholic steatohepatitis. Recent studies have demonstrated hepatic autophagy being impaired in NAFLD. In the present study, we investigated the impact of Rubicon, a Beclin1-interacting negative regulator for autophagosome-lysosome fusion, in the pathogenesis of NAFLD. In HepG2 cells, BNL-CL2 cells, and murine primary hepatocytes, Rubicon was posttranscriptionally up-regulated by supplementation with saturated fatty acid palmitate. Up-regulation of Rubicon was associated with suppression of the late stage of autophagy, as evidenced by accumulation of both LC3-II and p62 expression levels as well as decreased autophagy flux. Its blockade by small interfering RNA attenuated autophagy impairment and reduced palmitate-induced endoplasmic reticulum stress, apoptosis, and lipid accumulation. Rubicon was also up-regulated in association with autophagy impairment in livers of mice fed a high-fat diet (HFD). Hepatocyte-specific Rubicon knockout mice generated by crossing Rubicon floxed mice with albumin-Cre transgenic mice did not produce any phenotypes on a normal diet. In contrast, on an HFD, they displayed significant improvement of both liver steatosis and injury as well as attenuation of both endoplasmic reticulum stress and autophagy impairment in the liver. In humans, liver tissues obtained from patients with NAFLD expressed significantly higher levels of Rubicon than those without steatosis. Conclusion: Rubicon is overexpressed and plays a pathogenic role in NAFLD by accelerating hepatocellular lipoapoptosis and lipid accumulation, as well as inhibiting autophagy. Rubicon may be a novel therapeutic target for regulating NAFLD development and progression. (Hepatology 2016;64:1994-2014).

Original languageEnglish
Pages (from-to)1994-2014
Number of pages21
JournalHepatology
Volume64
Issue number6
DOIs
Publication statusPublished - Dec 1 2016

All Science Journal Classification (ASJC) codes

  • Hepatology

Fingerprint Dive into the research topics of 'Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice'. Together they form a unique fingerprint.

  • Cite this

    Tanaka, S., Hikita, H., Tatsumi, T., Sakamori, R., Nozaki, Y., Sakane, S., Shiode, Y., Nakabori, T., Saito, Y., Hiramatsu, N., Tabata, K., Kawabata, T., Hamasaki, M., Eguchi, H., Nagano, H., Yoshimori, T., & Takehara, T. (2016). Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice. Hepatology, 64(6), 1994-2014. https://doi.org/10.1002/hep.28820